Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion euros in its new R&D programme over the next five years. Of the total investment, 5 billion euros will go to preclinical R&D with 1.5 billion euro thereof planned for collaborations with external partners.
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine.
Pfizer expands its patient assistance program
- Details
- Category: Pfizer
In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free.
Merck recognized for digital workplace platform
- Details
- Category: Merck Group
The new EVA digital workplace at Merck, a leading science and technology company, was recently recognized with multiple Ragan Intranet Awards, an internationally renowned competition. The platform received prizes in the "Best Internal Social Networking" and "Best Design" categories.
AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
- Details
- Category: AstraZeneca
AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
Johnson & Johnson announces agreement to acquire Novira Therapeutics, Inc.
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The acquisition includes Novira's portfolio of novel antivirals, including its lead candidate, NVR 3-778.
Sanofi and BioNTech announce cancer immunotherapy collaboration and license agreement
- Details
- Category: Sanofi
Sanofi and BioNTech A.G. today announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).
More Pharma News ...
- Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity
- Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc.
- 'Science' says Abbott is a Top Employer
- Allergan plc confirms discussions regarding potential business combination transaction with Pfizer Inc.
- Novartis Foundation and partners launch new hypertension program in Ghana
- FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US
- Bristol-Myers Squibb reports third quarter financial results